NAOV
NanoVibronix, Inc.NASDAQHealthcareAs of 2026-04-04
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.04
P/S
0.75
EV/EBITDA
0.28
DCF Value
$-109.85
FCF Yield
-335.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
30.0%
Operating Margin
-351.8%
Net Margin
-129.7%
ROE
-11.7%
ROA
-6.4%
ROIC
-20.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $722.0K | $510.0K | $-1.12 |
| Q2 2025 | $494.0K | $-156.0K | $-1.03 |
| Q1 2025 | $1.0M | $-2.5M | $-3.98 |
| Q4 2024 | $444.0K | $-1.4M | $-4.21 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.06
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.